Mirae Asset Global Investments Co. Ltd. Purchases 538 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Mirae Asset Global Investments Co. Ltd. grew its position in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 0.6% in the first quarter, HoldingsChannel.com reports. The firm owned 85,614 shares of the biopharmaceutical company’s stock after acquiring an additional 538 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Horizon Therapeutics Public were worth $9,008,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Johnson Financial Group Inc. bought a new position in shares of Horizon Therapeutics Public during the fourth quarter worth $25,000. Covestor Ltd bought a new position in shares of Horizon Therapeutics Public during the fourth quarter worth $37,000. Citizens National Bank Trust Department bought a new position in shares of Horizon Therapeutics Public during the fourth quarter worth $38,000. Samalin Investment Counsel LLC bought a new position in shares of Horizon Therapeutics Public during the first quarter worth $41,000. Finally, Tcwp LLC bought a new position in shares of Horizon Therapeutics Public during the first quarter worth $41,000. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HZNP. BMO Capital Markets dropped their target price on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a research report on Thursday, August 4th. Morgan Stanley dropped their target price on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating for the company in a research report on Thursday, August 4th. The Goldman Sachs Group decreased their price target on shares of Horizon Therapeutics Public from $164.00 to $144.00 and set a “buy” rating on the stock in a research note on Thursday, August 4th. UBS Group downgraded shares of Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and decreased their price target for the company from $137.00 to $71.00 in a research note on Thursday, August 4th. Finally, StockNews.com downgraded shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Horizon Therapeutics Public currently has a consensus rating of “Moderate Buy” and an average price target of $117.22.

Insider Activity

In other news, EVP Andy Pasternak sold 4,850 shares of the stock in a transaction on Friday, July 29th. The shares were sold at an average price of $82.57, for a total value of $400,464.50. Following the sale, the executive vice president now owns 34,047 shares of the company’s stock, valued at $2,811,260.79. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Andy Pasternak sold 4,850 shares of the firm’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $82.57, for a total value of $400,464.50. Following the transaction, the executive vice president now owns 34,047 shares of the company’s stock, valued at approximately $2,811,260.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sean M. Clayton purchased 745 shares of Horizon Therapeutics Public stock in a transaction that occurred on Thursday, August 4th. The stock was bought at an average cost of $66.67 per share, for a total transaction of $49,669.15. Following the purchase, the executive vice president now directly owns 745 shares in the company, valued at $49,669.15. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 5,022 shares of company stock valued at $415,089. 2.50% of the stock is currently owned by company insiders.

Horizon Therapeutics Public Trading Up 0.8 %

Shares of HZNP opened at $63.48 on Wednesday. Horizon Therapeutics Public Limited has a twelve month low of $57.84 and a twelve month high of $120.54. The company has a market cap of $14.62 billion, a P/E ratio of 19.59, a P/E/G ratio of 1.58 and a beta of 1.21. The company has a current ratio of 4.05, a quick ratio of 3.79 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $69.08 and its 200-day simple moving average is $86.58.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.29). Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The firm had revenue of $876.40 million during the quarter, compared to analysts’ expectations of $938.82 million. During the same period in the prior year, the company posted $1.62 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts expect that Horizon Therapeutics Public Limited will post 4.23 EPS for the current year.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

See Also

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.